Demonstrates extended overall survival and fewer severe adverse events with nivolumab in advanced renal-cell carcinoma, indicating superior therapeutic benefit.
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: